Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) said its subsidiary, Jinzhou Avanc Pharmaceutical, obtained marketing registration approval from China's National Medical Products Administration for its Metaraminol Bitartrate Injection.
The drug is mainly used for prevention and treatment of hypotension, according to a Monday disclosure with the Hong Kong Exchange.